Targeting mesenchymal stem cell therapy for severe pneumonia patients  

作　　者：Guy Lam Yuan Zhou Jia-Xian Wang Yat-Ping Tsui 

机构地区：[1]School of Biomedical Sciences,University of Hong Kong,Hong Kong 999077,China [2]Research and Development,Help Therapeutics Co.Ltd.,Nanjing 211100,Jiangsu Province,China

出　　处：《World Journal of Stem Cells》2021年第2期139-154,共16页世界干细胞杂志（英文版）（电子版）

基　　金：Supported by the Project Contract for Technical Innovation Project for Small and Medium-sized Science and Technology Enterprises in Jiangning District,No.2020JSCX0563.

摘　　要：Pneumonia is the inflammation of the lungs and it is the world’s leading cause of death for children under 5 years of age.The latest coronavirus disease 2019(COVID-19)virus is a prominent culprit to severe pneumonia.With the pandemic running rampant for the past year,more than 1590000 deaths has occurred worldwide up to December 2020 and are substantially attributable to severe pneumonia and induced cytokine storm.Effective therapeutic approaches in addition to the vaccines and drugs under development are hence greatly sought after.Therapies harnessing stem cells and their derivatives have been established by basic research for their versatile capacity to specifically inhibit inflammation due to pneumonia and prevent alveolar/pulmonary fibrosis while enhancing antibacterial/antiviral immunity,thus significantly alleviating the severe clinical conditions of pneumonia.In recent clinical trials,mesenchymal stem cells have shown effectiveness in reducing COVID-19-associated pneumonia morbidity and mortality;positioning these cells as worthy candidates for combating one of the greatest challenges of our time and shedding light on their prospects as a nextgeneration therapy to counter future challenges.

关 键 词：PNEUMONIA Human mesenchymal stem cells IMMUNOMODULATION Alveolar protection Pandemic challenge Clinical trials 

分 类 号：R563.1[医药卫生—呼吸系统]